Two years ago, cancer was identified on a lobe of my left lung and the lobe was surgically removed. Now, a non-specific lesion has been identified on the remaining lobe of that lung (CT Scan). Is this new lesion likely to become malignant? The Mayo Clinic has developed a new analysis technique, based on CT Scans, for assessing the risk that one of these lesions will become malignant (the technique is referred to by the acronym “CANARY”). Supposedly, the new software that is the core of the CANARY technology is being commercialized by a firm called IMBIO. In the interest of getting the best possible diagnosis of my new lesion, I am interested in determining the availability of this new technology. However, attempts to contact the Mayo Clinic as well as IMBIO appear to have fallen upon deaf ears, as I have received no response after more than a month of inquiries at both institutions. If the CANARY technology is indeed now commercialized, why can’t I simply find out where, and under what terms, it’s available to cancer patients (including me)? I would appreciate a response and some appropriate guidance from a Mayo Clinic professional. Thanks.